press Mail Label No. ET575136221US

and invented by:

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. SBI-091

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONERFOR PATENTS

Box Patent Application

Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application invention entitled:

COMPOSITIONS AND METHODS FOR PROMOTING MYOCARDINGAL AND PERPHERAL ANGIOGENESIS

	Rama John										
If a	CON	۱TI	NUA	TIONAL	PPL	ICATION,	ched	k appropriate bo	x and supply t	he requisite information:	
Ò	Co	nti	nuat	ion 🗆	D	ivisional		Continuation-i	in-part(CIP)	of prior application No.:	
Wr	nich is	a:									
<u>.</u>	Coi	nti	nuati	ion 🗆	D	ivisional		Continuation-i	in-part(CIP)	of prior application No.:	
		nti	nuati	ion 🗆	D	ivisional		Continuation-i	in-part(CIP)	of prior application No.:	-
En	close	d a	ire:					Application	n Elements		
	1. 🛭	3	Filin	g fee as	cal	culated and	l trai	nsmitted as descr	ribed below		
	2. 🛭	⊴	Spe	cification	n ha	ving		2825	pages and in	cluding the following:	
		a.	×	Descrip	tive	Title of the	Inv	ention			
	ı	b.		Cross F	Refe	erences to F	Rela	ed Applications ((if applicable)		
		C.		Statem	ent	Regarding	Fed	erally-sponsored	Research/De	velopment(if applicable)	
		d.		Referer	nce	to Microfic	ne A	opendix (if applic	able)		
		e.	\boxtimes	Backgr	oun	d of the Inv	entic	on			
		f.	×	Brief Su	ımn	nary of the	Inve	ntion			
	1	g.	×	Brief De	esci	ription of the	e Dra	awings (if drawin	gs filed)		
		h.	×	Detaile	d De	escription					
		i.	×	Claim(s	s) as	Classified	Bel	ow			
		j.	×	Abstrac	t of	the Disclos	sure				

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. SBI-091

Total Pages in this Submission

		Application Elements (Continued)					
3.	×	Drawing(s) (when necessary as prescribed by 35 USC 113)					
	a.	Formal Number of Sheets					
	b.	☑ Informal Number of Sheets11					
4.		Dath or Declaration					
	a.	☐ Newly executed (original or copy) ☐ Unexecuted					
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)					
	c.	☐ With Power of Attorney ☐ Without Power of Attorney					
	d.	☐ <u>DELETIONOF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).					
5.		ncorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Sox 4b, is considered as being part of the disclosure of the accompanying application and is hereby ncorporated by reference therein.					
6.		Computer Program in Microfiche (Appendix)					
7.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)					
	a.	☐ Paper Copy					
	b.	Computer Readable Copy (identical to computer copy)					
	C.	☐ Statement Verifying Identical Paper and Computer Readable Copy					
		Accompanying Application Parts					
8.	×	AssignmentPapers (cover sheet & document(s))					
9.		37 CFR 3.73(B) Statement (when there is an assignee)					
10.		English Translation Document (if applicable)					
11.		nformation Disclosure Statement/PTO-1449					
12.		Preliminary Amendment					
13.	×	Acknowledgmentpostcard					
14.	×	Certificate of Mailing					
		☐ First Class 🕅 Express Mail (Specify Label No.): ET575136221US					

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. SBI-091

Total Pages in this Submission

Accompanying Application Parts (Continued)
Contified Convert Principle Decument/s) (if foreign principles alsimod)

Additional Enclosures (please identify below):	

Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(f), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

Page 3 of 4

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. SBI-091

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	19	- 20 =	0	×	\$18.00	\$0.00
indep. Claims	6	- 3 =	3	×	\$84.00	\$252.00
il Multiple Depender	nt Claims (checl	(if applicable)				\$0.00
BASIC FEE						
OTHER FEE (spe	cify purpose)					\$0.00
					TOTAL FILING FEE	\$992.00

A check in the amount of to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge and credit Deposit Account No. 09-0473 as described below. A duplicate copy of this sheet is enclosed.

☑ Charge the amount of \$992.00 as filing fee.

Credit any overpayment.

Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,

pursuant to 37 C.F.R. 1.311(b).

Timothy L. Sqott

Reg. No. 37,931

SULZER MEDICA USA INC.

3 East Greenway Plaza, Suite 1600

Houston, Texas 77046

Phone: 713-561-6369 Fax: 713-561-6380

Dated: 12/21/01

CC

ERTIFICATEOF No policant(s): Akella et	MAILING BY "EXPRESS al	MAIL" (37 CFR 1.10)	Docket No. SBI-091
Serial No.	Filing Date	Examiner	Group Art Unit
vention: COMPOSITI ANGIOGEN	ONS AND METHODS FOR E	PROMOTING MYOCARDINAL	AND PERIPHERAL
I hereby certify that the	following correspondence:		
Patent Application			
	(Identify type	of correspondence)	
is being deposited with	the United States Postal Serv	ice "Express Mail Post Office to A	ddressee" service under
(Date)		Amy Lewis (Typed of Prinsel Napse of Orson Malling Cor (Signature of Person Mailing Cor ET575136221U ("Express Mail" Mailing Labe	respondence)
	Note: Each paper must h	ave its own certificate of mailing.	